ClinicalTrials.gg
CompletedNCT06880328Updated Mar 17, 2025

18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia

A Phase 1 interventional study of Ralmitaront and Radiolabeled PET tracer [18F]-DOPA in Schizophrenia, sponsored by Hoffmann-La Roche. Completed at 4 sites in United States. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2019, 7 years 2 months ago, and no results have been posted to the registry.
  • Registered 6 years 4 months after the study started (first participant enrolled Nov 2018, registered Mar 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Schizophrenia by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Schizophrenia · Hoffmann-La Roche.

Enrollment
12th of 16
35 · median 294
Started
2018
with 1 other
Phase 1
5 of 19
none open now
Registered
19th of 19
by date

Among the 19 studies in Schizophrenia by Hoffmann-La Roche, this one is the 12th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2018, is one of 5 in phase 1, and was the 19th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 19 studies in Schizophrenia by Hoffmann-La Roche is open now. The open studies under Schizophrenia, anywhere →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 50 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Schizophrenia by Hoffmann-La Roche as a file.
02

Study summary

This study is an exploratory proof of mechanism (POM) study using PET/functional magnetic resonance imaging (fMRI) in a 2-period, 2-sequence, crossover design. The aim of the study is to confirm the potential of Ralmitaront to decrease dopamine synthesis capacity (DSC) - as measured by levels of F-DOPA - in the striatum of participants with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients with non-acute schizophrenia defined by diagnosis of schizophrenia as established by the mini-international neuropsychiatric interview (MINI)
  • Medically stable over 1 month and psychiatrically stable for at least 3 months prior to the screening visit
  • Patients with evidence of clear treatment response to antipsychotics as documented by chart information or reported by the patient or an informant considered reliable by the Investigator
  • Outpatient with no hospitalization for worsening of schizophrenia within 3 months prior to screening (hospitalization for social management within this time was acceptable)
  • At least one positive and negative syndrome scale (PANSS) positive subscale item from P1 (delusion), P3 (hallucination), P5 (grandiosity), or P6 (suspiciousness/persecution) of mild or greater severity (score .3), but below 7 (extreme severity)
  • (BMI) between 18 and 35 kg/m2 inclusive

Exclusion criteria

Exclusion Criteria:

  • Diagnosis for bipolar disorder, schizoaffective disorder or major depressive disorder based on
  • A prior or current general medical condition that might be impairing central nervous system (CNS) functioning (e.g., head trauma with persistent neurological or cognitive sequelae, dementia, seizure disorder, stroke, neurodegenerative, inflammatory, infectious, neoplastic, toxic, metabolic or endocrine disorders)
  • Average triplicate interval greater than 450 msec or other clinically significant abnormality on screening (ECG) as assessed by the Investigator or deputy based on centralized reading
  • Clinically significant abnormalities in laboratory safety test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis)
  • Positive result at screening for (HBV), (HCV, untreated), or (HIV)-1 and HIV-2. HCV patients who had been successfully treated and who tested negative for HCV ribonucleic acid (RNA), could be considered eligible for entry into the study
  • Patient at current significant risk of suicide or harming him or others according to the Investigator's judgment
  • Patients with a history of violent/suicidal/homicidal behavior or history of suicidal/homicidal command hallucinations in the past 10 years
  • Patients who have had 3 or more exacerbations associated with violent/suicidal/homicidal behavior or suicidal/homicidal command hallucinations (regardless of time)
  • History of electroconvulsive treatment (ECT)
  • Patients treated with long-acting injectable antipsychotic drugs or cariprazine
  • Patients with known history of treatment resistance or having received clozapine within 3 months of screening
  • Treatment with prohibited medication taken within 4 weeks (or within 5 times the elimination half-life of the medication) before the first study drug administration (whichever is longer). This included medications with known effects on cerebral blood flow.
  • Use of grapefruit, Seville orange or star fruit containing products within 1 week before the first study drug administration
  • Receipt of an drug within 90 days or 5 times the half-life of the investigational drug, whatever was longer, prior to baseline visit
  • Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per Investigator assessment)
  • Moderate-to-severe substance use disorder within 6 months of screening (excluding caffeine) as defined by DSM-5
  • Heavy smokers as defined by a high dependence score in the Fagerstrom Tolerance Scale (score ≥ 6)
  • Positive urine drug screen for amphetamines, methamphetamines, opiates, buprenorphine, methadone, cannabinoids, cocaine and barbiturates after and prior to randomization
  • Any sensorial impairment such as deafness and reduced visual acuity, which could not be corrected in the MRI scanner
  • Clinically significant abnormal findings on the baseline MRI images such as stroke, infarction, space-occupying lesion such as tumor, structural abnormalities, or vascular pathology
  • Known exposure to radiation in the last year that would mean the total exposure to radiation with participation in the study was likely to exceed 30 mSv
  • Donation of blood over 400 mL within 3 months prior to screening
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Sequence 1: Ralmitaront then Placebo

    Participants were given a daily dose of Ralmitaront during the treatment period of 14 days, followed by a 7 day washout period, and then a daily dose for 14 days with the placebo.

    Drug: Ralmitaront · Other: Radiolabeled PET tracer [18F]-DOPA · Drug: Placebo

  • Experimental
    Sequence 2: Placebo then Ralmitaront

    Participants were given a daily dose of the placebo during the 14 day period, followed by a 7 day washout, and then a daily dose of Ralmitaront for 14 days.

    Drug: Ralmitaront · Other: Radiolabeled PET tracer [18F]-DOPA · Drug: Placebo

Interventions

  • Participants were given a once 150 mg daily dose of Ralmitaront orally during the 14 day treatment period.

    Also known as: RO6889450

  • OtherRadiolabeled PET tracer [18F]-DOPA

    \[18 F\]-DOPA solution for injection is manufactured by the PET imaging centers according to specifications established for the tracer at the site. The injection will happen prior to the scan being done and will last for approximately 30 seconds.

  • DrugPlacebo

    Participants were given a daily dose of the placebo during the 14 day treatment period.

06

What researchers measure

Primary outcomes

  1. Influx Rate Constant (Ki) Value of [18F]-DOPA in the Whole Striatum, as Measured Using [18F]-DOPA PET Imaging

    Time frame: Baseline, and on Days 13-14 and Days 34-35

Secondary outcomes

  1. Bilateral Ventral Striatum Eigenvariates From the T-Contrast of Rewarded vs. Non-reward Expectation During the Monetary Incentive Delay (MID) Task, as Assessed Using fMRI

    Time frame: Baseline, and on Days 13-14 and Days 34-35

  2. Percentage of High Effort Choices Under Deterministic Reward Condition for High Reward in the Effort-Choice Benefit Task

    Time frame: Baseline, and on Days 13-14 and Days 34-35

  3. Mean Cerebral Blood Flow (CBF) in Different Brain Regions, as Measured by fMRI

    Time frame: Baseline, and on Days 13-14 and Days 34-35

  4. Bilateral Eigenvariate From Dorsolateral Prefrontal Regions Defined Based on the 2-back >0-back Contrast in the N-back Working Memory Task, as Assessed Using fMRI

    Time frame: Baseline, and on Days 13-14 and Days 34-35

  5. Incidence and Severity of Adverse Events (AEs)

    Time frame: From first dose until 14 days after the last dose of study treatment (up to 49 days)

  6. Incidence of Treatment Discontinuations Due to AEs

    Time frame: From first dose until 14 days after the last dose of study treatment (up to 49 days)

  7. Incidence of Vitals Sign Abnormalities (Resting and Orthostatic)

    Time frame: From first dose until 14 days after the last dose of study treatment (up to 49 days)

  8. Change From Baseline in ECG Intervals: PQ (PR), QRS, QT, RR and QTcF

    Time frame: Baseline, Days 13-14, 21, 34-35, and during the follow-up visit (14-18 days after last dose)

  9. Incidence of Laboratory Abnormalities, Based on Hematology, Clinical Chemistry, and Urinalysis Test Results

    Time frame: From first dose until 14 days after the last dose of study treatment (up to 49 days)

  10. Concentration of Ralmitaront and Ralmitaront-derived Metabolite(s) Per Time-point

    Time frame: Days 2, 7, 13-14, 23, 28, 34-35, and during the follow up visit (14-18 days after last dose)

  11. Area Under the Curve (AUCss) of Ralmitaront and Ralmitaront-derived Metabolite(s)

    Time frame: Days 2, 7, 13-14, 23, 28, 34-35, and during the follow up visit (14-18 days after last dose)

  12. Cmax of Ralmitaront and Ralmitaront-derived Metabolite(s)

    Time frame: Days 2, 7, 13-14, 23, 28, 34-35, and during the follow up visit (14-18 days after last dose)

07

Study locations

4 sites
  • Parexel California Clinical Trials Medical Group
    Glendale, California 91206, United States
  • Collaborative Neuroscience Network Inc.
    Torrance, California 90502, United States
  • CBH Health
    Gaithersburg, Maryland 20877, United States
  • St Louis Clinical Trials
    Saint Louis, Missouri 63141, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Sep 2019, 9 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 9 months is close to that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Mar 17, 2025
StartActual
Nov 7, 2018
Primary completionActual
Sep 4, 2019
CompletionActual
Sep 4, 2019
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06880328
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Nov 7, 2018
Primary completion
Sep 4, 2019
Completion
Sep 4, 2019
Last update
Mar 17, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ralmitaront

Start the discussion